The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.
Panelists discuss the presentation and management of a case involving HER2-mutated metastatic non–-small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback